However, independently of a possible interaction of regulatory cells and the tumor, it may be necessary to take into consideration the different subsets of immune regulatory cells when decisions are made on immunotherapies, since some patients may be more prone to respond while some cHL patients may be identified who may benefit most from blocking PD-1/PD-L1 interactions. Here, PDCD1 is linked to classic Hodgkin lymphoma.